ATP sensitive potassium channel openers are of potential benefit in ischaemic heart disease.
Cavero
I
I
Rhone-Poulenc Rorer, Centre de Recherche de Vitry-Alfortville, Vitry sur Seine, France.
Premmereur
J
J
D001578:Benzopyrans / Q000627:therapeutic use; D019806:Cromakalim; D004095:Dihydropyridines / Q000627:therapeutic use; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000378:metabolism; D009206:Myocardium / Q000166:cytology; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D020108:Nicorandil; D010847:Picolines / Q000627:therapeutic use; D020110:Pinacidil; D015221:Potassium Channels / Q000187:drug effects*; D011714:Pyrans / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D014665:Vasodilator Agents / Q000627:therapeutic use
D001578:Benzopyrans; D004095:Dihydropyridines; D006146:Guanidines; D010847:Picolines; D015221:Potassium Channels; D011714:Pyrans; D011758:Pyrroles; D014665:Vasodilator Agents; D019806:Cromakalim; D009536:Niacinamide; D020108:Nicorandil; C061043:aprikalim; C061050:bimakalim; D020110:Pinacidil; D000254:Sodium-Potassium-Exchanging ATPase